Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.
3 reports, 2 independent
Updated Sep 14
Gone quiet
- Reports
- 3
- Developments
- 6
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Astex Pharmaceuticals and Newcastle University formed a strategic alliance with Hoffmann-La Roche to license breast cancer compounds.Sub-event
- Pfizer and Genmab are collaborating on TIVDAK, which combines Genmab's antibody with Pfizer's ADC technology.Sub-event
- ADC Therapeutics received accelerated approval for its drug from the FDA.Sub-event
- Adagene Inc. presented data regarding its ADG126 therapy at a CSCO meeting, with mentions of locations including Jinan and Suzhou.Sub-event
- Hutchison MediPharma and AstraZeneca are jointly developing savolitinib TKI, with clinical data presentations scheduled for WCLC 2025 and CSCO Annual Meeting 2025.Sub-event
Rivals are competing in the ADC market, with co-developers of trastuzumab pamirtecan highlighted.1 source
Keep exploring
The entities involved
-
Hoffmann-La Roche
Swiss healthcare company
-
BioNTech
Biotechnology company from Germany
Nothing else this week.
-
DUALITY
Czech company
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company
Coverage
Newest first; wire copies grouped- proactiveinvestors.com
- Clinical Trials ArenaBioNTech and Duality’s ADC trumps Kadcyla, but analysts unimpressed BioNTech and DualityBio are seeking the Chinese approval of trastuzumab pamirtecan after it outperformed Roche’s Kadcyla (trastuzum